Pharma Business Week articles from October 2004

Pharma Business Week archives from October 2004

Bonefos accepted for filing and granted priority review by FDA.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Schering AG, Germany (SCH, SHR) announced that Bonefos (clodronate) has been accepted for filing and designated for priority review by the U.S. Food and Drug Administration (FDA). Berlex...

Forecast: Generic erosion may stunt growth of bipolar disorder drug market.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Decision Resources, Inc., forecasts that generic erosion will significantly stunt the growth of the bipolar disorder drug market in the United States. According to the new Pharmacor study entitled...

Companies to commence second phase III trial for milnacipran in Q4.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Cypress Bioscience, Inc., (CYPB) expects its partner, Forest Laboratories (FRX) to initiate the second phase III trial evaluating milnacipran for the treatment of fibromyalgia syndrome (FMS) during the...

IND allowed for ALS treatment.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Aeolus Pharmaceuticals, Inc., (AOLS) announced that it has been notified by the U.S. Food and Drug Administration (FDA) of their allowance of Aeolus' Investigational New Drug application (IND) to begin...

TheraCLEC selected for FDA's Continuous Marketing Application Pilot 2 program.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Altus Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) has selected TheraCLEC for participation in the Continuous...

Cholesterol drugs may open door for more OTC switches.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- With the rapid growth of the highly dynamic - and extremely profitable - market for cholesterol-lowering medications, or statins, a switch from prescription to over-the-counter (OTC) status is likely...

11.5% of Biodyne acquired by technology company.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- QuantumBit Induction Technology Inc. (OTC:QBIT) has acquired 11.5% of Biodyne Inc. Biodyne Inc. is a Houston-based, privately held, biomedical development firm, and has engaged Biodyne in the...

FDA approves Methylin Chewable Tablets, Methylin Oral Solution for ADHD.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Alliant Pharmaceuticals, Inc., announced U.S. Food and Drug Administration (FDA) approval of Methylin Chewable Tablets and Methylin Oral Solution for the treatment of ADHD. The two products are the...

DNA binding to viral enzyme may serve as new target for antiviral drugs.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Scientists at the U.S. Department of Energy's Brookhaven National Laboratory and the Albert Einstein College of Medicine have produced the first molecular-scale images of DNA binding to an adenovirus...

Paper describes new treatment for prevention of postsurgical adhesions.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- ARC Pharmaceuticals, Inc., announced that Dr. Johanne Cashman, director of preclinical research, published a paper entitled "Camptothecin-loaded Films for the Prevention of Postsurgical Adhesions" in...

Food Allergy Buddy dining card launched.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Philip Lempert, known by both consumers and the food industry as the "Supermarket Guru" and an expert analyst on consumer, marketing and food safety trends, announced the launch of the Food Allergy...

Immunoglobulins might be promising treatment for AD.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Intravenous immunoglobulin might offer a promising treatment for Alzheimer disease, suggests preliminary research. Deposits of amyloid protein, which progressively damage brain tissue, are a...

Request submitted to FDA for designated new animal drug listing.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Amarillo Biosciences, Inc., (AMAR) announced that it has submitted requests to the U.S. Food & Drug Administration's (FDA) Office of Minor Use and Minor Species Animal Drug Development (MUMS) for...

Company updates the European development status of micafungin.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Fujisawa Pharmaceutical Co., Ltd., announced that it now expects the approval of its injectable candin antifungal agent micafungin in Europe to be in the first half of 2006 because additional data have...

Study shows ACP-103 improves clinical profile of haloperidol treatment.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Acadia Pharmaceuticals, Inc., (ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders,...

Potential asthma monoclonal antibody to enter phase I clinical trial.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology (CATG) will be starting a phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent...

Regular sustained combination therapy may reduce asthma exacerbations.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- New data presented at the 14th annual European Respiratory Society (ERS) Congress in Glasgow have revealed the results of the EXCEL (EXacerbation Control Evaluated in a 6 month Long) study, a head to...

Scientists discover link between serotonin and airway allergic inflammation.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Scientists at the La Jolla Institute for Molecular Medicine (LJIMM) have discovered that serotonin, a naturally occurring neurotransmitter that is elevated in the blood of asthmatics, can directly cause...

Pharma company announces positive prostate drug trial results.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced new 1-year follow-up results from phase 2 testing of NX-1207, the company's investigational new drug for benign prostatic hyperplasia (BPH). ...

Researchers identify a cardiolipin-remodeling enzyme in the mouse.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- "ALCAT1 represents the first identified cardiolipin-remodeling enzyme from any living organism," researchers say. "Cardiolipin is a major membrane polyglycerophospholipid that is required for the...

Biopharm firm plans to develop radioprotective agents against nuclear terrorism.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Vyrex Corporation (VYRX) is proceeding with plans to use its antioxidant and prodrug technologies to develop radioprotective agents against nuclear/radiologic terrorism. The first such agent,...

Freestyle Mini, Precision Xceed blood glucose monitors launched in Europe.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Abbott Laboratories introduced the FreeStyle Mini and Precision Xceed blood glucose monitoring systems for Europe at the 40th Annual Meeting of the European Association for the Study of Diabetes in...

European marketing authorization issued for expanded use of Gliadel Wafer.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Guilford Pharmaceuticals Inc. (GLFD) announced that its proprietary treatment for brain cancer, Gliadel Wafer (polifeprosan 20 with carmustine implant), has been granted extended marketing authorization...

Orphan drug designation granted for Antineoplastons A10 and AS2-1.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Burzynski Research Institute (BRI) (BZYR) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidates Antineoplastons A10 and AS2-1 for the...

Biopharmaceutical company receives $1.5 million from exercise of warrants.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- RegeneRx Biopharmaceuticals, Inc., (OTCBB:RGRX) announced that it received $1.5 million from Defiante Farmaceutica, L.d.a., a wholly owned subsidiary of the Italian pharmaceutical group, Sigma-Tau, in...

Consumer products company confirms first quarter guidance.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- The Procter & Gamble Company (NYSE:PG) confirmed previously announced earnings guidance for the July - September quarter in line with analysts' current consensus estimate. The current consensus...

Financial results, clinical pipeline update provide by pharma company.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology (CATG) announced financial results for the 9 months ended June 30, 2004, a business update for the period since the interim results on May 17, 2004, and a clinical pipeline...

Hemaseel maker provides Q3 update.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Haemacure is pursuing the development of its proprietary fibrin sealant (Hemaseel HMN) and thrombin (Hemaseel Thrombin) products and is currently negotiating an agreement for the manufacture of product...

Home infusion therapy company provides 2004 financial results.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Option Care, Inc., (NASDAQ:OPTN) affirmed previously issued guidance for 2004 diluted earnings per share of $0.84 to $0.87. Raj Rai, Option Care's chief executive officer commented, "We continue to...

Pharmaceutical company reiterates commitment to Mylan Laboratories transaction.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- King Pharmaceuticals, Inc., (KG) reiterated that the company is steadfastly committed to its previously announced combination with Mylan Laboratories Inc. (MYL), as King believes the combination makes...

Pharmaceutical firm reports best year ever for sales, profits.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Aceto Corporation (ACET), a global distributor of chemically derived pharmaceuticals, biopharmaceuticals, specialty chemicals and agrochemicals, announced record results of operations for the fourth...

Venture capital company closes Inaugural fund under management.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Quaker BioVentures announced that it has closed its inaugural fund with approximately $280 million under management. Founded in early 2002 by veterans from the life sciences industry, Quaker is...

2004 Employer and Coalition Service Profiles Supplement released.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Health Industries Research Companies (HIRC) has released its 2004 Employer and Coalition Service Profiles Supplement. The 2004 Profiles Supplement focuses on key demographic and attitudinal data...

Clinical research organization implements quality management initiative.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- PRA International (PRA) announced the global implementation of the PRA Management System (PRAMS), a fully integrated quality management initiative. PRA International is committed to attaining the...

Company announces US$24.4 million in sterols sales agreement.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Forbes Medi-Tech, Inc., (FMTI) announced that it has secured a sterols sales agreement for US$24.4 million over a 3-year period beginning in January 2005. This new customer agreement is between...

ENT-103 maker provides progress report and litigation update.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Entropin, Inc., (ETOP), a development-stage pharmaceutical company focused on the pain-therapy market, provided a progress report on its lead drug candidate, ENT-103, and a litigation update. ...

Enterprise renames itself.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- PhytoMedical Technologies, Inc., (PYTO), has successfully completed its name change from Enterprise Technologies, Inc. The new name more accurately reflects the company's entry into the research,...

Financing for international distribution of Snorenz/SnoreAway announced.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Med Gen Inc. (MDGN) has reached an agreement whereby Med Gen's secured lender would help finance the distribution of Snorenz/SnoreAway and Good Nights Sleep into the international marketplace. Med...

Genomics company expands, relocates to new facility.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Agencourt Bioscience Corporation, a provider of genomic services and nucleic acid purification products to the life sciences industry, celebrated the grand opening of its new corporate headquarters in...

Healthcare REIT closes new $300 million credit facility, declares dividend.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Ventas, Inc. (VTR) said its subsidiary, Ventas Realty, Limited Partnership, closed its new $300 million secured revolving credit facility initially priced at 125 basis points over LIBOR. The new...

Hurricanes delay company's relocation plans.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- MTS Medication Technologies (MPP) announced it will be moving its operations in October 2004 rather than September 2004 as previously announced. This delay was due in large part to construction...

ImpactRx selects wireless solution for data collection, transport needs.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Sprint (FON) announced an agreement to provide ImpactRx with a wireless solution for its data collection and transport needs. Through a multiyear agreement, Sprint will provide wireless voice and...

Instrument maker announces new headquarters.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Argonaut Technologies (AGNT), a provider of chemistry instruments and consumables to help the pharmaceutical industry accelerate drug development, announced the relocation of its corporate headquarters...

Licensing agreement announced for hydrodynamic gene delivery technology.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Mirus Bio Corporation has entered into an agreement with Genzyme Corporation covering research applications of Mirus' proprietary hydrodynamic gene delivery technology. Under this agreement,...

Partnership to promote R&D programs, technologies, products in Japan.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Jurilab has established a partnership with Summit Pharmaceuticals International Corporation (SPI) to promote Jurilab's research and development programs, technologies, and products in Japan. Under...

Pharma company unites divisions to become more R&D driven.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Daiichi Pharmaceutical Co., Ltd. will establish an R&D Division, uniting the former Development Division and Research Division, to bolster its competitiveness in terms of global R&D as part of efforts...

PSA era is over for predicting prostate cancer risk, say Stanford researchers.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine...

Phase I study of TNFerade for soft tissue sarcoma published.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- GenVec, Inc., (NASDAQ:GNVC) announced that results from a phase 1 study for its lead product candidate, TNFerade, in patients with soft tissue sarcoma of the extremities were published in the Clinical...

Gene therapy for bladder cancer shows strong results in animal studies.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Gene therapy that causes the bladder to act like a "bioreactor" to produce and secrete the anticancer agent interferon-alpha has shown dramatic benefits in preclinical tests, say researchers at The...

Pharma company finds anticancer drug effective in reducing tumor size.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Solbec Pharmaceuticals Ltd (ASX:SBP) announced that its anticancer drug SBP002 was effective in reducing tumor size in some patients involved in a phase I trial, and have requested to continue taking...

Radiation therapy center operator announces financing deal.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- OnCURE Medical Corp. (OnCURE) announced that it has completed a $15 million debt financing to fund future acquisitions and restructure its existing line of credit and other debt. Approximately $7...

Radiation therapy management company expands into New Jersey.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Radiation Therapy Services, Inc., (NASDAQ:RTSX) announced that it has entered into definitive purchase agreements to acquire three radiation centers in New Jersey, which currently treat more than 60...

Successful pre-IND meeting for AVR118 with FDA reported.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Advanced Viral Research Corp. (ADVR) announced that the company had a successful pre-investigational new drug (IND) meeting with the U.S. Food & Drug Administration (FDA) at the end of August. ...

Yeast-based immunotherapy causes mutation-selective tumor remission.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Ras-targeted, whole yeast-based immunotherapy resulted in mutation-selective tumor remission. "Activating mutations in Ras oncoproteins represent attractive targets for cancer immunotherapy, but...

Enrollment in phase 3 trial of anidulafungin for invasive candidiasis complete.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Vicuron Pharmaceuticals Inc. (MICU) announced that the company has completed enrollment in its phase 3 clinical trial of anidulafungin for invasive candidiasis/candidemia. The double-blind,...

Animal health company launches trials on dogs with heart diseases.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- In October 2004 Orion Pharma Animal Health will launch extensive clinical field studies on dogs with heart diseases. The aim of the project is to develop treatment for dogs with heart problems. ...

Par Pharmaceutical enters marketing agreement to its nitroglycerin lingual spray.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- NovaDel Pharma Inc. (AMEX:NVD) announced that is has entered into a licensing agreement with Par Pharmaceutical (NYSE:PRX) to market its nitroglycerin lingual spray. In June, NovaDel filed a new...

New dye directly reveals activated proteins in living cells.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- A series of experiments shows for the first time that novel biosensor dyes can directly reveal activation of proteins in individual living cells. The research, led by Dr. Klaus M. Hahn, professor of...

COPD patients prefer Respimat Soft MistTM Inhaler.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Respimat Soft MistTM Inhaler (SMI) represents a major step forward in inhalation therapy, resulting in high patient preference and satisfaction over other devices. The results of the analysis were...

New research targets management of COPD.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- New research into the management of chronic obstructive pulmonary disease (COPD), a debilitating respiratory illness, shows that patients treated with the inhaled drug Spiriva (tiotropium) experience...

Spiriva reduces COPD exacerbations, related health resource burden, data shows.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Spiriva (tiotropium) significantly reduced exacerbations and health resource utilization compared with placebo in patients with Chronic Obstructive Pulmonary Disease (COPD), according to data presented...

Study shows clinical trials last longer than expected.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Clinical trials last 42% longer than expected in phase I, 31% longer in phase II, and 30% beyond planned deadlines in phase III, according to a study recently conducted by Cutting Edge Information. ...

Clinical trials of drug for internal genital warts broadened.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Stressgen Biotechnologies (SSB) announced that it has broadened the clinical program for its lead drug candidate, HspE7. The company has expanded the program through the enrollment of patients in a...

Diversa gets milestone payments for identifying protein therapeutic candidates.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Diversa Corp. (DVSA) announced that the company has identified several lead protein therapeutic candidates under its research and product development agreement with Syngenta (SYT), resulting in...

Patient enrollment begun for central precocious puberty phase 3 implant study.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Valera Pharmaceuticals it has initiated patient enrollment for a pivotal phase 3 trial of a 1-year implant for the hormonal treatment of central precocious puberty (CPP), an affliction characterized by...

Phase 2 protocals submitted to U.S. FDA for clinical trials of synthetic blood.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Synthetic Blood International, Inc. (SYBD), has submitted the first of a series of phase 2 clinical trial protocols for Oxycyte to the U.S. Food and Drug Administration (FDA). Oxycyte is the...

Outline provided for developing national clinical trials registry.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- For the first time since announcing its support of a national clinical trials registry, the American Medical Association outlined to Congress key criteria needed to make such a registry effective. ...

CRO group establishes global influence with Input to EMEA.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- The Association of Clinical Research Organizations (ACRO), representing companies that are key participants in the clinical development of new medicinal products, is consulting regularly with European...

Alliance to discover, develop multiple small molecule oncology products.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Sunesis Pharmaceuticals, Inc., and Biogen Idec (BIIB) announced a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play...

Additional drug discovery deal with Synaptic signed.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- 7TM Pharma announced that 7TM Pharma and Synaptic, a wholly owned subsidiary of Lundbeck, have signed a new collaborative research agreement again focused on 7TM Pharma's drug discovery approach. ...

Contractual agreement signed with Pfizer for cognitive tests.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- CogState Limited (CGS) announced that it has signed a Master Service Agreement with Pfizer, Inc. The agreement will provide the contractual basis for any future use by Pfizer during clinical...

Evotec enters agreement to help identify GPCR modulator-based new medicines.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Evotec OAI, AG, (EVT) and Evotec Neurosciences, GmbH, announced a 3-year research collaboration with Boehringer Ingelheim. The companies aim to jointly identify and develop small molecule...

Pharmaceutical companies sign drug discovery deal.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Anadys Pharmaceuticals, Inc., (ANDS) and Aphoenix, Inc., an emerging chemical genomics company in Japan, announced that they have entered into a 3-year drug discovery collaboration. Under the terms...

Pharmaceutical firm to license Accelrys software.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Accelrys, Inc., (ACCL) announced an agreement with Bayer Healthcare AG under which Bayer has licensed a comprehensive library of life science modeling software from Accelrys. These tools, which...

Research agreement signed with Organon for assays.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- BioImage A/S announced it has signed a research agreement with Organon. The agreement outlines the use of BioImage's Redistribution assays for pathway profiling of selected lead compounds produced,...

Supply agreement signed for needle-free vial adapter product.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Bioject Medical Technologies, Inc., (BJCT), a developer of needle-free drug delivery systems, announced that it has entered into a supply agreement with a pharmaceutical company for the sale of...

Oral surgeon warns: Herbals, surgery, and anesthesia don't always mix.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- The woman who swears by gingko biloba wonders why her mouth won't stop bleeding after wisdom tooth surgery. What she doesn't know is that the herbal remedy she takes religiously to enhance mental...

Company reports oxypurinol clinical results.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Cardiome Pharma Corp. (CRME) announced the release of interim results for 2 physician-sponsored clinical studies for oxypurinol in congestive heart failure (CHF) patients. The results were...

FDA conditional approval granted to use Petal Stent System in BOSS trial.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Advanced Stent Technologies (AST), Inc., received U.S. Food & Drug Administration (FDA) conditional approval to incorporate its bare metal novel Petal coronary bifurcation stent and delivery system into...

Novel therapy has positive effect on lipid uptake in cystic fibrosis patients.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Arexis AB announced the completion of a successful phase II clinical trial around their novel human enzyme replacement therapy for the treatment of fat mal-absorption in patients with cystic fibrosis....

Possible sources of microarray signal correlation bias identified.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Possible sources of signal correlation bias in DNA microarrays have been identified. "DNA microarray analyses commonly use two spectrally distinct fluorescent labels to simultaneously compare...

Dental plan urges patients to share medical history with dentist.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- According to the Academy of General Dentistry, dental patients should mention everything about their health, even if it they think it doesn't relate to the mouth. "Forgetting to share information...

Phase 2a trial results reported for investigational drug in atopic dermatitis.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Nucryst Pharmaceuticals Corp., a subsidiary of The Westaim Corporation, announced results from its initial phase 2a efficacy and safety study of NPI 32101 in a cream formulation in adult patients with...

Pharma company changes name of dermatology business to Intendis.
October 4, 2004... 2004 OCT 4 - (NewsRx.com & NewsRx.net) -- Schering AG (FSE: SCH, NYSE: SHR) announced that its new dermatology company will be called "Intendis." The Intendis Group will incorporate Schering AG's worldwide dermatology business and operate...